SNSE Sensei Biotherapeutics, Inc.

Nasdaq senseibio.com


$ 8.96 $ -0.60 (-6.06 %)    

Thursday, 20-Nov-2025 15:35:14 EST
QQQ $ 585.42 $ -26.21 (-4.28 %)
DIA $ 458.18 $ -8.50 (-1.82 %)
SPY $ 652.73 $ -20.17 (-3 %)
TLT $ 89.28 $ 0.29 (0.32 %)
GLD $ 374.86 $ -0.35 (-0.09 %)
$ 10.015
$ 10.00
$ 8.81 x 11
$ 9.16 x 100
$ 9.30 - $ 10.00
$ 5.00 - $ 18.35
105,157
na
12.63M
$ 5.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-28-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 02-29-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-29-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-15-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-30-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-downgrades-sensei-biotherapeutics-to-neutral

HC Wainwright & Co. analyst Matthew Keller downgrades Sensei Biotherapeutics (NASDAQ:SNSE) from Buy to Neutral.

 sensei-biotherapeutics-board-determines-to-discontinue-development-of-solnerstotug-and-initiate-comprehensive-review-of-strategic-alternatives-to-maximize-shareholder-value

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of ...

 sensei-biotherapeutics-releases-results-from-the-phase-12-dose-expansion-study-of-solnerstotug-presented-at-esmo-2025-the-data-addressed-the-critical-challenge-of-secondary-resistance-to-immune-checkpoint-inhibitors-where-treatment-success-rates-are-typically-below-5

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of ...

 hc-wainwright--co-maintains-buy-on-sensei-biotherapeutics-raises-price-target-to-30

HC Wainwright & Co. analyst Joseph Pantginis maintains Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy and raises the pr...

 sensei-biotherapeutics-to-implement-1-for-20-reverse-stock-split-of-issued-and-outstanding-shares-effective-june-16-2025

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of ...

 hc-wainwright--co-assumes-sensei-biotherapeutics-at-buy-announces-price-target-of-5

HC Wainwright & Co. analyst Matthew Kelsey assumes Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION